NCT04425382 (DOLCI) is a clinical trial of Darunavir/Cobicistat in Coronavirus, sponsored by Hamad Medical Corporation.

Who is sponsoring NCT04425382?

NCT04425382 is sponsored by Hamad Medical Corporation.

What drugs are being tested in NCT04425382?

Interventions in NCT04425382: Darunavir/Cobicistat, Lopinavir/Ritonavir.

What condition does NCT04425382 study?

NCT04425382 studies Coronavirus, COVID, Pneumonia.

Is NCT04425382 still recruiting?

NCT04425382 is currently completed. Last updated 16 August 2022.

Last reviewed 2022-08-16 · How we verify

NCT04425382: DOLCI

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Darunavir/Cobicistat vs. Lopinavir/Ritonavir in COVID-19 Pneumonia in Qatar

Completed Last updated 16 August 2022

What this trial tests

trial testing Darunavir/Cobicistat in Coronavirus in 400 participants. Completed in 30 September 2020.

Timeline

1 March 2020

Primary endpoint
31 July 2020

30 September 2020

Quick facts

Lead sponsor	Hamad Medical Corporation
Status	Completed
Study type	OBSERVATIONAL
Enrollment	400
Start date	1 March 2020
Primary completion	31 July 2020
Estimated completion	30 September 2020
Sites	1 location across Qatar

Drugs / interventions tested

Darunavir/Cobicistat — full drug profile →
Lopinavir/Ritonavir

Conditions studied

Coronavirus — all drugs for Coronavirus →
COVID — all drugs for COVID →
Pneumonia — all drugs for Pneumonia →

Sponsor

Hamad Medical Corporation — full company profile →

Who can join

18 and older, any sex, with Coronavirus or COVID. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Coronavirus Disease 2019 (COVID-19) is a disease caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus. It was first isolated in Wuhan, China in December 2019 and then rapidly spread to the rest of the world posing a severe threat to global health. Many therapeutics have been investigated for the treatment of this disease with inconclusive outcomes. Protease inhibitors are one of the proposed agents, but their use is limited to their significant drug interactions and side effects. The aim of this study is to compare the efficacy and safety outcomes of Darunavir/Cobicistat versus Lopinavir /Ritonavir in the treatment of patients with COVID-19 pneumonia in Qatar.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Drug repurposing approach to fight COVID-19.
Singh TU, Parida S, Lingaraju MC, Kesavan M, et al · · 2020 · cited 299× · PMID 32889701 · DOI 10.1007/s43440-020-00155-6
Darunavir ethanolate: Repurposing an anti-HIV drug in COVID-19 treatment.
Chavda VP, Gajjar N, Shah N, Dave DJ. · · 2021 · cited 23× · PMID 36575695 · DOI 10.1016/j.ejmcr.2021.100013
Antiretroviral drug activity and potential for pre-exposure prophylaxis against COVID-19 and HIV infection.
Copertino DC, Casado Lima BC, Duarte RRR, Powell TR, et al · · 2022 · cited 21× · PMID 33734021 · DOI 10.1080/07391102.2021.1901144
COVID-19 associated complications and potential therapeutic targets.
Monpara JD, Sodha SJ, Gupta PK. · · 2020 · cited 21× · PMID 32926918 · DOI 10.1016/j.ejphar.2020.173548
Approaching coronavirus disease 2019: Mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2.
Lisi L, Lacal PM, Barbaccia ML, Graziani G. · · 2020 · cited 20× · PMID 32710969 · DOI 10.1016/j.bcp.2020.114169
Efficiency of antiviral treatment in COVID-19.
Negrut N, Codrean A, Hodisan I, Bungau S, et al · · 2021 · cited 18× · PMID 33968179 · DOI 10.3892/etm.2021.10080
A Comprehensive Summary of the Knowledge on COVID-19 Treatment.
Peng Y, Tao H, Satyanarayanan SK, Jin K, et al · · 2021 · cited 18× · PMID 33532135 · DOI 10.14336/ad.2020.1124
A novel nano therapeutic using convalescent plasma derived exosomal (CP<sup>Exo</sup>) for COVID-19: A combined hyperactive immune modulation and diagnostics.
Anand K, Vadivalagan C, Joseph JS, Singh SK, et al · · 2021 · cited 15× · PMID 33991505 · DOI 10.1016/j.cbi.2021.109497

Verify or expand the search:

Other trials of Darunavir/Cobicistat

Trials testing the same drug.

NCT03864406 — Impact of Steady State Cobicistat and Darunavir/Cobicistat on the Pharmacokinetics and Pharmacodynamics of Oral Anticoag · Phase 1 · completed
NCT03123848 — A Study to Evaluate the Pharmacokinetics (PK) of Darunavir (DRV) and Cobicistat (COBI) After a Single Oral Administratio · Phase 4 · completed

Other recruiting trials for Coronavirus

Currently open trials in the same condition.

NCT04772170 — Observational Digital Biomarker Discovery in Respiratory Virus Challenge Studies · recruiting
NCT05868239 — Impact of Aerosol Box Use During Cardiopulmonary Arrest: A Multicenter Study · NA · recruiting
NCT04359836 — A Study to Explore the Role of Gut Flora in COVID-19 Infection · recruiting
NCT04376034 — Convalescent Plasma Collection and Treatment in Pediatrics and Adults · Phase 3 · recruiting
NCT04568148 — COVID-19 Biorepository · active not recruiting

Other Hamad Medical Corporation trials

Trials by the same sponsor.

NCT07333209 — Scheduled Positioning With a Peanutball(SPP) on Labor Outcomes Among Primiparous Women Under Epidural Analgesia · NA · recruiting
NCT07270939 — Optimizing Enteral Nutrition Regimen for Critically Ill Patients · NA · not yet recruiting
NCT07307508 — Efficacy of Scalp Block in Managing Post Subarachnoid Hemorrhage Headache in Critically Ill Patients. A Single Centre Ra · NA · recruiting
NCT06622577 — The Effect of Dietary Management and Cysteine Supplementation on Growth Parameters and Biochemical Control for Pediatric · NA · not yet recruiting
NCT06887855 — Enhancing Post-Stroke Dysphagia Rehabilitation · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04425382 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hamad Medical Corporation
Last refreshed: 16 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04425382.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing